Johnson & Johnson

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

Retrieved on: 
Wednesday, March 6, 2024
Research, Infectious Diseases, Finance, Clinical Trials, Professional Services, Biotechnology, AIDS, Pharmaceutical, Health, Science, Infection, Bangladesh Technical Education Board, HIV/AIDS, RAMS, Janssen Pharmaceuticals, Failure, Aes, Rilpivirine, Fungal infection, GSK, NIAID, CROI, Research and development, Arm, ISR, Life, ACTG, Data monitoring committee, Pfizer, Johnson & Johnson, Partner (business rank), Conference, ART, History, MPH, Male, ViiV Healthcare, DSMB, Mental health, HIV, SOC, Viral load, VF, Vaccine

Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.

Key Points: 
  • Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.
  • Participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression.
  • 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC {difference -14.4 (98.75% CI–29.8%, -0.8%)}.
  • Three participants in the LA-ART arm had serious injection site reactions (ISR) and one participant discontinued due to an ISR.

Morningstar Indexes Selected by IMX Health for First Healthcare Futures Exchange Product Offering

Retrieved on: 
Tuesday, March 5, 2024
Professional Services, Health, Hospitals, Finance, Pharmaceutical, Biotechnology, Eli Lilly, Hospital, Multimedia, Morningstar, Inc., Growth, Johnson & Johnson, Index, UnitedHealth Group, Health care, Ecosystem, IMX, Contract management, Cryptocurrency

Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced that the Intelligent Medicine Exchange (“IMX”), the first futures and options exchange focused on the healthcare economy, has aligned with Morningstar Indexes to offer its first futures product.

Key Points: 
  • Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced that the Intelligent Medicine Exchange (“IMX”), the first futures and options exchange focused on the healthcare economy, has aligned with Morningstar Indexes to offer its first futures product.
  • The IMX exchange was designated by the Commodity Futures Trading Commission in January of this year.
  • The new futures product from IMX Health will be based on the Morningstar US Healthcare Index , which measures the performance of approximately 170 U.S. public healthcare companies representing biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities and medical equipment and supplies.
  • Amelia Furr, global head of sales for Morningstar Indexes, said: “We are excited to offer a Morningstar index as the basis for futures on IMX exchange.

FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio

Retrieved on: 
Friday, March 1, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Therapy, Foresite Capital, GV, Artificial intelligence, Colorectal cancer, Record, Cancer, Growth, Johnson & Johnson, Helicon, MBA, Symbiosis, Data science, World Health Organization, Patient, MPH, Oncology, ARCH Venture Partners, Farallon Capital, Pharmaceutical industry

Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.

Key Points: 
  • Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.
  • The financing will fund the ongoing clinical development of FOG-001, the company’s first-in-class intracellular TCF-blocking β-catenin inhibitor currently being evaluated in a Phase 1/2 study in solid tumors.
  • The round will also accelerate the development of its robust portfolio of unique discovery programs, deepen its data science capabilities and strengthen its core Helicon therapeutics platform.
  • “Millions of colorectal cancer patients have been told by their oncologists that no more can be done for them.

Impact Podcast with John Shegerian Announces March’s All-Star Guest Lineup of Sustainability Innovators

Retrieved on: 
Thursday, February 29, 2024
TV and Radio, Podcast, Technology, Professional Services, General Entertainment, Entertainment, Environmental, Social and Governance (ESG), Other Technology, Environment, Hardware, Sustainability, Clorox, Procter, General Motors, Virginity, Albertsons, T-Mobile, Whole Foods Market, Panasonic, LexisNexis, Gensler, UPS, General Mills, PwC, Salesforce, McKinsey & Company, ITT, Electronics, Johnson & Johnson, HP, Gap Inc., Wells Fargo, The Home Depot, Ford, EBay, ESPN, Procter & Gamble, Colgate-Palmolive, FedEx, Professional corporation, Amazon Music, Google Podcasts, The Hershey Company, ESG, JetBlue, Molson Coors, Hertz, BMW, Webby Awards, Accenture, Verizon Communications, Tractor Supply Company, Adobe, Comerica, Merck, Intel, Best Buy, ERI, Kraft Heinz, Dell, IBM, Visa, Texas Instruments, Entrepreneurship, AT&T, KPMG, Music

Impact Podcast with John Shegerian has announced its roster of guests for March, featuring a who’s who of circularity, ESG, sustainability and corporate responsibility all-stars from many of the world’s leading brands.

Key Points: 
  • Impact Podcast with John Shegerian has announced its roster of guests for March, featuring a who’s who of circularity, ESG, sustainability and corporate responsibility all-stars from many of the world’s leading brands.
  • The Webby Award honored show is hosted by John Shegerian, Co-Founder, Chairman and CEO of ERI , the nation’s leading fully integrated IT and electronics asset disposition provider and cybersecurity-focused hardware destruction company.
  • Impact Podcast guests are invited to share with listeners first-hand accounts of how they are able to help make the world a better place on a daily basis.
  • “Our Impact Podcast roster of experts features leaders who work every day to help make our world a better place.

Growth Opportunities and Business Models Driving Sustainability in Pharmaceuticals Industry: Eco-friendly Products, Design Innovation, and Multi-Stakeholder Partnerships Supporting Initiatives - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Health, Pharmaceutical, European Green Deal, Research, AstraZeneca, Paris Agreement, Growth, Johnson & Johnson, Amcor, ESG, GHG, COVID-19, United Nations, Sustainable Development Goals, Business, Fine chemical

The "Growth Opportunities and Business Models Driving Sustainability in Pharmaceuticals Industry" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities and Business Models Driving Sustainability in Pharmaceuticals Industry" report has been added to ResearchAndMarkets.com's offering.
  • The pharmaceutical (pharma) industry is undergoing significant regulatory changes resulting from the European Green Deal and the Paris Agreement.
  • The study discusses key trends and factors driving the growth of the sustainability program as well as restraints to adoption and their implications.
  • Pharma industry companies to action in the sustainability space are provided, and the ESG programs are mapped against the 6P framework.

Brightcove Announces Financial Results for Fourth Quarter and Fiscal Year 2023

Retrieved on: 
Thursday, February 22, 2024
Software, Networks, Entertainment, Internet, Apps, Applications, Technology, General Entertainment, Digital Marketing, TV and Radio, Marketing, Audio, Video, Communications, CFO, Holocene, MLS, AI, Analytics, Growth, Johnson & Johnson, Ford Motor Company, HubSpot, Dropbox, Google Drive, BCOV, GAAP, MotoAmerica, Metadata, Organization, Emmy Awards, Public expenditure, Eastern Time Zone, DeBevoise, Salesforce, Marketo, Inc., Pinterest, Depreciation, Partnership, Video game

Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.
  • Loss from operations was $2.3 million for the fourth quarter of 2023, compared to loss from operations of $6.0 million for the fourth quarter of 2022.
  • Net loss was $2.5 million, or a loss of $0.06 per diluted share, for the fourth quarter of 2023.
  • Cash flow provided by operations was $4.2 million for the fourth quarter of 2023, compared to cash flow provided by operations of $5.7 million for the fourth quarter of 2022.

Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

Retrieved on: 
Thursday, February 22, 2024
Research, Other Health, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Molecule, Organic chemistry, Viral, Senior, Janssen Pharmaceuticals, Dartmouth College, SAB, Neuroscience, Beclabuvir, PTC Therapeutics, University, RNA, Jan Vansina, RSV, HIV-1, Atomic, Johnson & Johnson, Stroke, Bristol Myers Squibb, MBA, BMS, Therapy, Journal, HCV, PTC, Drug discovery, Meanwell, McArdle Laboratory, American Academy, Royal Society, Daclatasvir, Harvard University, Asunaprevir, Doctor of Philosophy, Thrombosis, Rutgers University, Patient, Outline of physical science, American Chemical Society, Deep learning, Publication, Cancer, Medicinal chemistry, Pharmaceutical industry

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).

Key Points: 
  • Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
  • “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
  • Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies.
  • “They have demonstrated tremendous progress integrating deep learning foundation models with experimental results to be able to predict and optimize RNA structures to enable rational drug design.

Otolith Labs Expands Leadership Team with the Appointment of Dan Wagner as its Chief Commercial Officer and Raphael Michel to its Board of Directors

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Medical Devices, Other Health, Health, Health Technology, Therapy, Boston Scientific, Eargo, Marketing, Hansen Medical, CCO, Olympus Corporation, Stanford University, IPO, Vertigo, Otolith, Johnson & Johnson, Patient, DSM-IV codes, DME, University of California, Berkeley, Pharmaceutical industry

Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Dan Wagner as Chief Commercial Officer (CCO) and Raphael Michel as an independent Board member.

Key Points: 
  • Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Dan Wagner as Chief Commercial Officer (CCO) and Raphael Michel as an independent Board member.
  • Otolith Labs’ technology is a head-worn wearable device being investigated for the treatment of vertigo episode symptoms associated with vestibular migraines.
  • “Dan has been working with Otolith in an advisory role for over 5 years, so we are thrilled to have him full-time.
  • “Raphael is one of our earliest industry advisors and has been providing critical counsel to Otolith Labs since 2016.

Digital Surgery Technologies Market Report 2024 - Improved Precision and Promising Post-Operative Rehabilitation through Pre-Surgical Planning

Retrieved on: 
Wednesday, March 6, 2024
Real-World Evidence, Investment, Name, Virtual reality, Hospital, University of Miyazaki, Algorithm, Privacy, AI, Education, Traction, Research, ROI, Digital, Pain, 3D, Growth, Johnson & Johnson, Use, Surgeon, Government, RWE, Country, Immersion, Health care, Interest, Patient, Region, Acceleration, Medicine, Patient safety, VR, Trust, Augmented reality, Microsoft, Software, Dentistry

The key factors driving the growth of the global digital surgery technologies market include the increasing interest of technologists and start-ups in surgery-related innovation, improved precision offered by digital surgery techniques, and promising post-operative rehabilitation through pre-surgical planning.

Key Points: 
  • The key factors driving the growth of the global digital surgery technologies market include the increasing interest of technologists and start-ups in surgery-related innovation, improved precision offered by digital surgery techniques, and promising post-operative rehabilitation through pre-surgical planning.
  • Increasing Investment and Funding for Digital Surgery Technologies: Digital surgery technologies, owing to their transformative potential to enhance precision, optimize workflows, and improve patient outcomes, are rapidly changing the landscape of healthcare.
  • Investing in digital surgery technologies is not just about financial gains; it's an investment in the future of healthcare.
  • Based on application, the digital surgery technologies market has been led by augmented reality and virtual reality, which held a 48.40% share in 2022.

Children's Mercy Research Institute Announces Sponsorship from Johnson & Johnson and Noah's Bandage Project to Increase Diversity in Pediatric Cancer Clinical Trials at Children's Mercy Kansas City

Retrieved on: 
Tuesday, March 5, 2024
Research, Gender identity, DEI, Education, Friends, Quality of life, Cancer, Language, Communication, Johnson & Johnson, Create, Health, CMRI, Health equity, Mercy, Nursing

KANSAS CITY, Mo., March 5, 2024 /PRNewswire/ -- Children's Mercy Research Institute (CMRI) announced a combined sponsorship from Johnson & Johnson* and Noah's Bandage Project of nearly $640,000 to increase education and awareness of racial disparities in pediatric clinical trials.

Key Points: 
  • KANSAS CITY, Mo., March 5, 2024 /PRNewswire/ -- Children's Mercy Research Institute (CMRI) announced a combined sponsorship from Johnson & Johnson* and Noah's Bandage Project of nearly $640,000 to increase education and awareness of racial disparities in pediatric clinical trials.
  • "This funding will allow us to start to eliminate barriers to trial recruitment and participation, ensuring effective interventions and treatments that benefit all children."
  • Provide ongoing DEI training for cancer researchers and staff, including information on pediatric cancer disparities, implicit bias, microaggressions, and culturally sensitive communication and recruitment strategies.
  • The project aligns with Johnson & Johnson's "Our Race to Health Equity" (ORTHE) initiative to address underrepresentation in healthcare.